Abstract: Introduction: incidence of aortic valve stenosis is 3rd in the group of cardio-vascular diseases. Most important questions of aortic valve replacement (AVR) are: prosthesis effective orifice area (EOA) sufficiency for certain patient and need of posterior aortoplasty (PA). Each prosthesis of certain number has technical data and size. Reasonable frequency of posterior aortoplasty is a discussed question. Aim: was to analyze echocardiographic data in two groups: isolated AVR and AVR + PA in order to study the reasonable frequency of posterior aortoplasty application while using stented bioprosthesis NeoCor-21 «UniLine». Materials and methods: 99 patients with bioprosthesis NeoCor-21 «UniLine» implantation were enrolled in study for investigation of problem of aortoplasty need. According to application/absence of posterior aortoplasty patients were divided in two groups. In postoperative period groups were compared in echocardiographic data calculations: left ventricle end-diastolic volume (LV EDV), ejection fraction (LV EF), stroke volume (LV SV), peak and mean valve gradients. Indexes were calculated and compared: stroke volume index (SVI) and prosthesis effective orifice area index (EOAI). Results: the group of AVR + PA consisted of 14 (14,14%) patients. Immediate postoperative echocardiographic calculations revealed no statistic difference between two groups: in left ventricle end diastolic volume (LV EDV), ejection fraction (LV EF), stroke volume (LV SV), peak and mean valve gradients, stroke volume index (SVI) and valve effective orifice area index (EOAI). Group without posterior aortoplasty had slightly higher end diastolic volume (LV EDV), stroke volume (LV SV), peak and mean valve gradients. Opposite patients with posterior aortoplasty had slightly higher ejection fraction (LV EF), stroke volume index (SVI), slightly less peak and mean valve gradients. Left ventricle function was more optimal in the posterior aortoplasty group. Conclusion: in our practice, incidence of posterior aortoplasty in using stented bioprosthesis NeoCor-21 «UniLine» was 14,14%. Echocardiographic calculations of postoperative data demonstrated that this frequency was reasonable. Probably posterior aortoplasty is to be applied more frequently. Conflict of interest: the authors declare no conflict of interest. References 1. Bokeriya LA, Belaya G. Methods of echocardiographic assessment of aortic valve hemodynamics after prosthetics: methods and precautions. Kreativnaya kardiologiya-Creative cardiology. 2012; 6(1): 73-79 [In Russ]. 2. Iqbal A, Panicker VT, Karunakaran J. Patient prosthesis mismatch and its impact on left ventricular regression following aortic valve replacement in aortic stenosis patients. Indian J Thorac Cardiovasc Surg. 2019; 35: 6-14. https://doi.org/10.1007/s12055-018-0706-3 3. Malhotra A. Prosthesis patient mismatch: myth or reality? Indian J Thorac Cardiovasc Surg. 2019; 35: 3-5. https://doi.org/10.1007/s12055-018-0708-1 4. Rashimtoola SH. The problem of valve prosthesis-patient mismatch. Circulation. 1978; 58: 20-24. 5. Sazonenkov MA, Ismatov KhH, Prisyazhnyuk EI, et al. Comparison of the manufacturers technical specification with postoperative results in four types of stented bioprostheses in the aortic position. Actualnye problemy mediciny. 2020; 43(1): 113-123 [In Russ]. 6. Klyshnikov KYu, Ovcharenko EA, Shcheglova NA, Barbarash L.S. Functional characteristics of Uniline bioprostheses. Kompleksnye problemy serdechno-sosudistykh zabolevaniy. 2017; 3: 6-12 [In Russ]. https://doi.org/10.17802/2306-1278-2017-6-3-6-12 7. Manufacturers information. ZAO «NeoCor» 1978-2020 [In Russ]. https://neocor.ru/aortalnyyklapan-3 8. Nicks R, Cartmill T, Bernstein L. Hypoplasia of the aortic root. The problem of aortic valve replacement. Thorax. 1970; 25(3): 339-346. 9. Rittenhouse EA, Sauvage LR, Stamm SJ, et al. Radical enlargement of the aortic root and outflow tract to allow valve replacement. Ann Thorac Surg. 1979; 27(4): 367-73. 10. Clinical guidelines: Aortic stenosis. Association of Cardiovascular Surgeons of Russia. Moscow 2020 [In Russ]. 11. Manouguian S, Seybold-Epting W. Patch enlargement of the aortic valve ring by extending the aortic incision into the anterior mitral leaflet. New operative technique. J Thorac Cardiovasc Surg. 1979; 78(3): 402-412. 12. Belov YuV, Charchyan ER, Katkov AI, et al. Influence of the discrepancy between the diameter of the prosthesis and the patient's body surface area on the long-term results of aortic valve replacement. Kardiologiya i serdechno-sosudistaya khirurgiya. 2016; 9 (2): 46-51 [In Russ]. https://doi.org/10.17116/kardio20169246-51 13. Pibarot P, Magne J, Leipsic J, et al. Imaging for Predicting and Assessing Prosthesis-Patient Mismatch After Aortic Valve Replacement. JACC Cardiovasc Imaging. 2019; 12(1): 149-162. https://doi.org/10.1016/j.jcmg.2018.10.020 14. Tam DY, Dharma C, Rocha RV, et al. Early and late outcomes of aortic root enlargement: a multicenter propensity score-matched cohort analysis. J Thorac Cardiovasc Surg. 2020; 160: 908-19. https://doi.org/10.1016/j.jtcvs.2019.09.062 15. Aortic valve replacement with smaller prostheses in elderly patients: does patient prosthetic mismatch affect outcomes? J Card Surg. 2013; 28(4): 341-7. 16. Dumani S, Likaj E, Dibra L, et al. Aortic Annular Enlargement during Aortic Valve Replacement. Open Access Maced J Med Sci. 2016; 15; 4(3): 455-457. https://doi.org/10.3889/oamjms.2016.098 17. S? MP, Zhigalov K, Cavalcanti LRP, et al. Impact of aortic annulus enlargement on the outcomes of aortic valve replacement: a meta-analysis. Semin Thorac Cardiovasc Surg. 2021; 33(2): 316-325. 18. Aortic Root Enlargement Is Safe and Reduces the Incidence of Patient-Prosthesis Mismatch: A Meta-analysis of Early and Late Outcomes. Can J Cardiol. 2019; 35(6): 782-790.
Abstract: Current indications for transcatheter aortic valve replacement (TAVR) are limited for inoperable and high risk patients only. Meanwhile, TAVR may be successfully performed in young patients with low risk and with high technical and functional results according to short- and long-term follow-up. 54 patients underwent TAVR, 7 (12,9%) of them were younger than 65. Cause for endovascular procedure was the presence of oncological process in liver/autoimmune hepatitis/liver cirrhosis/severe bronchial asthma/atherosclerotic lesion of major vessels/severe diabetes mellitus. In 3 cases additional visualization method (intracardiac ultrasound examination) was necessary. All patients underwent implantation of CoreValve. Technical success was 100%. Function of valves was satisfactory. Light near-valve regurgitation was found in 6 cases, valve regurgitation class II was found in 1 case with decrease to class I after treatment. Intracardiac ultrasound examination is useful to attend successful results in this group of patients. References 1. 2012 ACCF/AATS/SCAi/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement. JACC. 2012; 59: 1200-1254. 2. Lemos PA, Lee CH, Degertekin M, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. JACC. 2003; 41: 2093-2099. 3. Ong A.T., Serruys P.W., Aoki J., et al. The unrestricted use of paclitaxel versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at 4. Hoye A., Tanabe K., Lemos P.A., et al. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. JACC. 2004; 43: 1954-1958. 5. Rao S.V., Shaw R.E., Brindis R.G., Klein L.W., Weintraub W.S., Peterson E.D. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am. J. Cardiol. 2006; 97: 1478 -1481. 6. Beohar N., Davidson C.J., Kip K.E., et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007; 297: 1992-2000. 7. Grines C.L. Off-label use of drug-eluting stents putting it in perspective. JACC. 2008; 51: 615-617. 8. Piazza N., Otten A., Schultz C., et al. Adherence to patient selection criteria in patients undergoing transcatheter aortic valve implantation with the 9. Eltchaninoff H., Prat A., Gilard M., et al. Transcatheter aortic valve implantation: earlyresults of the FRANCE (FRench Aortic National CoreValve and Edwards) registry. Eur. Heart J. 2011; 32:19-197. 10. Zahn R., 11. Rodes-Cabau J., Webb J.G., Cheung A., et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. JACC. 2010; 55:1080-1090. 12. Tamburino C., Capodanno D., Ramondo A., et al. incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation. 2011; 123: 299-308. 13. Webb J.G., Altwegg L., Boone R.H., et al. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation. 2009; 119: 3009-3016. 14. Piazza N., Grube E., Gerckens U., et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroIntervention. 2008; 4: 242-249. 15. Leon M.B., Smith C.R., Mack M., et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N. Engl. J. Med. 2010; 363: 1597-1607. 16. Smith C.R., Leon M.B., Mack M.J., et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N. Engl. J. Med. 2011; 364: 2187-2198. 17. Lee D.H., Buth K.J., Martin B.J., et al. Frail patients are at increased risk for mortality and prolonged institutional care after cardiac surgery. Circulation. 2010; 121: 973-978. 18. Roques F., Nashef S.A., Michel P., et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur. J. Cardiothorac. Surg. 1999; 15: 816-822. 19. Lange R., Bleiziffer S., Mazzitelli D., et al. improvements in Transcatheter Aortic Valve implantation Outcomes in Lower Surgical Risk Patients. JACC. 2012; 59: 280-287
